Xolatryp Protects Cells through Mitochondrial Stabilisation
| Stock | Nyrada Inc (NYR.ASX) |
|---|---|
| Release Time | 16 Sep 2025, 9:53 a.m. |
| Price Sensitive | Yes |
Xolatryp Protects Cells through Mitochondrial Stabilisation
- Further analysis confirms Xolatryp reduced mitochondrial calcium ion loading in the brain
- Results provide further preclinical evidence of Xolatryp's mechanism of action in mitigating secondary brain injury
- Nyrada remains on track to commence Phase IIa clinical trial of Xolatryp in Q1 2026 for acute myocardial infarction
Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company, has provided further information from its collaborative traumatic brain injury (TBI) study with the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney. The study sought to evaluate the efficacy of Xolatryp in a penetrating TBI rodent model and concluded that Xolatryp significantly preserved brain tissue integrity. As a further analysis, an additional cohort of animals underwent TBI followed by a 72-hour continuous intravenous infusion of Xolatryp or vehicle. The results confirmed that Xolatryp helps preserve mitochondrial health by improving calcium handling, thus protecting the brain's energy centres from reactive oxygen species (ROS) related damage. This further analysis increases Nyrada's confidence that Xolatryp's protective effects on mitochondria will also reduce heart damage, as ROS and calcium-driven mitochondrial damage occur in both brain injury and myocardial ischemia reperfusion injury (MIRI). The study demonstrated that systemic administration of Xolatryp after penetrating TBI in vivo resulted in mitochondria that, once isolated, had significantly enhanced calcium buffering capacity, indicating that Xolatryp crosses the blood-brain barrier, engages its molecular target (TRPC3/6/7 ion channels), and confers neuroprotection in terms of mitochondrial protection within a living system. Nyrada remains on track to commence its Phase IIa clinical trial of Xolatryp in the first quarter of calendar 2026 targeting patients with acute myocardial infarction.
Nyrada remains on track to commence its Phase IIa clinical trial of Xolatryp in the first quarter of calendar 2026 targeting patients with acute myocardial infarction.